Delivery Order SPE2DR25D1017-SPE2DR26F8YMS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,846.76 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed price contract. The award, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this pharmaceutical delivery order and functions as a...
- The Defense Logistics Agency awarded a $5,123.39 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Rexulti 1 mg tablets (30-count units). The contract, which is a firm fixed price delivery order with no set-aside designation, is scheduled for completion by September 22, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $30,339.39 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed price arrangement. The award, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's larger contract vehicle. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Rexulti 1 mg tablets (30-count units) with a ceiling value of $6,446.12. This firm fixed-price delivery order is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The contract is non-set-aside and was competitively awarded....
- The Defense Logistics Agency awarded a delivery order valued at $26,659.20 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count packages) on September 16, 2025, with completion targeted for September 17, 2025. This firm fixed-price delivery order represents a non-competitive set-aside transaction and will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $10,036.57 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on August 26, 2025, with an ultimate completion date of August 27, 2025, and represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the delivery order from its Conshohocken facility. This...
- The Defense Logistics Agency awarded a delivery order valued at $8,861.23 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on September 4, 2025, with an ultimate completion date of September 5, 2025, and does not utilize a set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this delivery order. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $3,043.89 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count packages) on July 14, 2025, with completion scheduled for July 15, 2025. This firm fixed price, competitively awarded delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The work...
- The Defense Logistics Agency awarded a $41,480.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This firm fixed-price, competitively awarded contract with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $2,846.60 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count package). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 24, 2025. The award was issued on September 23, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DR25D1017Indefinite Delivery Contract
- SPE2DR25D1017-SPE2DR26F8YMSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,013.98 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed-price contract. The order, awarded on October 24, 2025, with an ultimate completion date of October 27, 2025, represents a non-competitive delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). This IDC, valued at $999.999 billion and extending through December 2026, serves as a comprehensive pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to military healthcare systems globally. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement. The company's delivery orders under its DLA IDC demonstrate consistent capability to fulfill federal healthcare requirements across multiple therapeutic domains, including neurological treatments, diabetes management, pain management, and specialized medical supplies. This particular delivery order for Rexulti, an antipsychotic medication, reflects the company's ongoing role in supporting Defense Health Agency and other federal healthcare system needs through its established prime vendor relationship with DLA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 10/24/25 |